The global oncology adjuvants market was valued at around US$ 506.01 Million at the end of 2021. The market is projected to register a 4.60% CAGR and top a valuation of US$ 829.86 Million by 2032.
The increasing prevalence of cancers cases across the globe is the primary factor responsible for the markets growth.
Oncology adjuvant therapy is a type of cancer therapy that includes cancer treatment after the primary therapy is completed. The fundamental goal of oncology adjuvant therapy is to lower the risk of cancer recurrence. Chemotherapy, targeted therapy, radiation therapy, hormone therapy, or biological therapy are all examples of oncology adjuvant therapy. Before choosing an appropriate adjuvant therapy, oncologists take into account a number of elements, such as statistical data.
The primary goal of oncology adjuvant therapy is to eliminate the danger of cancer recurrence in order to increase the odds of survival for cancer patients. Through oncological surgery and adjuvant therapy, oncology adjuvant therapy is utilized to treat numerous cancers, including kidney carcinoma and some types of brain cancer. These tumours can also include colon, lung, breast, prostate, and other gynaecological malignancies.
| Attributes | Details |
|---|---|
| Oncology Adjuvants Market Value in 2021 | US$ 506.01 Million |
| Oncology Adjuvants Market Value in 2032 | US$ 829.86 Million |
| Oncology Adjuvants Market CAGR (2022 to 2032) | 4.60% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for oncology adjuvants is supposed to drive due to increasing prevalence of cancer which ultimately surge demand for cancer hospitals. Cancer treatment centres frequently employed the procedure to raise the efficiency of initial care and hence enhance patient outcomes. Additionally, it is anticipated that an increase in cancer incidence and funding for cancer research will fuel market expansion.
Moreover, changing lifestyles and increasing in habits such as smoking, unhealthy diet, physical inactivity, and others are also supposed to increase the risk of cancer, boosting the market’s growth. For instance, in 2018, according to
International Agency For Research on Cancer (IARC), about 17.0 million new cancer cases were found globally, and around 9.5 million cancer death. Also, the predicted that the global burden of cancer is anticipated to grow about 27.5 million by 2040.
The oncology adjuvants market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America dominated the regional oncology adjuvant market due to the presence of numerous cancer research centres in the region. Additionally, market expansion in this region is anticipated to be aided by the rising incidence of cancer. Also, it is anticipated that enhanced R&D efforts to provide cutting-edge cancer treatments will support market expansion in the region.
Moreover, Asia Pacific is supposed to grow fastest over the forecast duration due to an increase in per capita healthcare spending for higher quality. Growing R&D initiatives and a rise in cancer treatment demand in the area are anticipated to expand market opportunities. In addition, the region's expanding number of cancer hospitals and the increasing acceptance of new technology both contribute to the market's expansion.
Principal Consultant
Eli Lilly, Amgen, BMS, Biogen, Sanofi, AstraZeneca, Pfizer, Hengrui Medicine, Hisun Pharmaceutical, Yibai Pharmaceutical, SL Pharmaceutical, Zhendong Pharmaceutical, Main Luck Pharmaceuticals, Sanjiu Medical, and Livzon Pharmaceutical
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.60% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered | Application, Indication, End-User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, North Africa, Turkey, Israel |
| Key Players | Eli Lilly; Amgen; BMS; Biogen; Sanofi; AstraZeneca; Pfizer; Hengrui Medicine; Hisun Pharmaceutical; Yibai Pharmaceutical; SL Pharmaceutical; Zhendong Pharmaceutical; Main Luck Pharmaceuticals; Sanjiu Medical; Livzon Pharmaceutical |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global oncology adjuvants market is anticipated to register a CAGR of 4.60% during the forecast period.
Eli Lilly, Amgen, BMS, Biogen, Sanofi, AstraZeneca, Pfizer, Hengrui Medicine, Hisun Pharmaceutical, Yibai Pharmaceutical, SL Pharmaceutical, Zhendong Pharmaceutical, Main Luck Pharmaceuticals, Sanjiu Medical, and Livzon Pharmaceutical, among others are some prominent oncology adjuvants market players.
Explore Healthcare Insights
View Reports
Oncology Adjuvants Market
